Operational Spend, Tied to Structured Output
Tie every dollar of trial spend to measurable, AI-validated execution output.
A Day in the Life of a Clinical Trial CFO
The forecast is moving — again. A vendor invoice doesn't reconcile to milestone progress. A fixed-price program is sliding toward a margin call. The board wants a clear line from AI investment to operational KPIs.
The numbers are visible. The execution behind them is not. Operational spend keeps drifting from measurable output.
Maxis AI ties supervised execution back to financial KPIs — making throughput, cycle time and capacity countable.
Human-in-the-loop validation · Audit traceability · Governed execution
The Pressures Clinical Trial CFOs Carry Every Day
Spend Without Output Visibility
Operational spend is hard to tie to measurable output — milestone slippage drives forecast variability across the portfolio.
Margin Pressure At Scale
Fixed-price programs absorb every coordination delay — margins compress as variability grows across vendors and CROs.
AI Investment Without KPI Tie-Back
AI spend is rising, but the link to operational KPIs — cycle time, throughput, capacity — is not always defensible to the board.
Finance needs structured visibility into execution — not more reports about it.
Industry Reality
- Trial cost continues to rise faster than throughput improvements.
- Vendor and CRO portfolios fragment cost ownership.
- Forecast confidence depends on execution predictability.
- Boards expect measurable returns on AI and operational investment.
- Audit and inspection readiness sits on the same evidence base as financial reporting.
The CFO conversation is shifting from cost control to structured output.
How Maxis AI Is Built for Trial Finance Leaders
Maxis AI produces predictable cycle times and structured throughput — measurable against operational and financial KPIs. Every action is logged for both regulatory and financial audit.
Operational spend stops being a black box. Cycle time, throughput, capacity and margin become countable, comparable and defensible at the board table.
From Pain to Outcome: How Maxis AI Works for You
Pain Point
AI Capability
Outcome
Operational spend disconnected from measurable output.
Supervised execution tied to defined cycle-time KPIs.
Spend tied to structured, measurable throughput.
Forecast variability driven by milestone slippage.
Predictable cycle times under governed execution.
Improved forecast confidence across studies.
Margin pressure on fixed-price programs.
Structured execution capacity under one accountable layer.
Improved delivery margins on fixed-price work.
Limited visibility into vendor and CRO execution.
Cross-portfolio execution logs and oversight.
Real-time visibility into vendor performance.
Hard to tie AI investment to operational KPIs.
Outputs measured against defined cycle-time and throughput KPIs.
AI investment defensible at the board table.
Identified Recruitment Risk 4 Months Earlier, Preventing ~$120M Revenue Loss
Understand how a Clinical Trial CFO improved financial risk visibility across a $50M–$200M+ portfolio by identifying enrollment and site performance risks earlier.
+6pts
Delivery Margin
40%
Forecast Variance Reduction
100%
Audit Traceability
1.0x
Spend-to-Output Tie-Back
All You Need to Know
Supervised execution produces predictable cycle times and structured throughput — tying operational spend directly to measurable milestones.
Outcomes are measured against operational and financial KPIs — cycle time, throughput, capacity and margin.
Yes. Every action is logged for both financial and regulatory audit, validated under human oversight.
Yes. Maxis AI operates as a supervised execution layer over existing clinical and reporting systems.
Forecast confidence, vendor visibility and margin improvement on fixed-price programs.
Explore the Agentic AI Platform.
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.